

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Catalano et al.      Confirmation No.    2460  
Application No.:    10/501,636      Art Unit:            1626  
Filed:                July 15, 2004      Examiner:    Rei Tsang Shiao  
For:                CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS  
                         CATHEPSIN K INHIBITORS

Customer No.:    23347

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT**


Sir:

This paper is submitted in response to the Office Action mailed September 18, 2006. Early examination of the application on the merits is earnestly solicited.

The Examiner has restricted the claims of the present patent application into five groups. In addition, the Examiner has required the Applicant to pick a single species for search purposes. Applicants elect the claims of Group I for prosecution in the present application, and further elect the species shown in Example 3 (Benzyl (2S)-2-{[(3S)-3-({[(1-benzylcyclopentyl)oxy]carbonyl}amino)-2-oxoheptanoyl]amino}propanoate) for purposes of the search. In the accompanying preliminary amendment, applicants have amended the claims to conform with the restriction requirement.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Kathryn L. Coulter  
Attorney for Applicants  
Registration No. 45,889

Date: 11/9/2006

GlaxoSmithKline  
Five Moore Drive, PO Box 13398  
Research Triangle Park, North Carolina 27709  
Telephone: (919) 483-1467  
Facsimile: (919) 483-7988